Oral-B® Announces its Partnership with the iADH (International Association of Disability and Oral Health) to Help Make Oral Care More Accessible and Positive for All
14.9.2022 16:08:00 EEST | Business Wire | Press release
Oral-B, the leading innovator in oral health, announces partnership with the International Association of Disability and Oral Health (iADH) as part of the brand’s drive to make oral care more inclusive, accessible, and positive for people with disabilities, their caregivers, and everyone in between.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220823005621/en/
Oral-B® announces its partnership with the International Association of Disability and Oral Health as part of the overall brand mission to make oral care more inclusive, accessible, and positive for all. Pictured (left to right): Benjamin Binot, Oral Care Senior Vice President at Procter & Gamble and Prof Alison Dougall, President of the International Association of Disability and Oral Health (iADH). Credit: Djibrann Hass
Approximately 166 million people in Europe are affected by a disability in some way and recent research reveals that a third (1/3) of those experience gum issues due to struggles with maintaining their oral health1. Oral-B is on a mission to ensure that everybody has an equitable oral care experience - whether that be at the dentist practice, easily accessible and personalised tips and tricks or with the products that are used at home to maintain oral health.
Benjamin Binot, P&G Europe Oral Care Senior Vice President says: “As the leading innovator in oral health for over 70 years and the #1 dentist recommended brand, we recognise the importance of making oral care accessible to all – and continuously listen to people's experiences with disabilities to understand how we can help them. Through this work, we have learned that oral health care struggles amongst this audience are most common because many haven’t been taught the skills they need to brush their teeth effectively, they experience a sense of inevitability about their teeth deteriorating and may be especially anxious in the dentist’s chair. As a brand, we recognize our responsibility to help ensure that oral care is accessible to all and we are proud to partner with the iADH to work to improve the experience for people living with disabilities.”
The first step of this partnership is to co-create a ‘Positive Practices’ training program designed to train and educate dental practices on how to become more confident and inclusive when it comes to their patients.
Alison Dougall, iADH President says; “We are delighted to be working alongside Oral-B to address the significant oral health inequalities experienced by people with disabilities in Europe, through innovation, education, research and advocacy. By working together, we aim to make a positive difference to the oral care experience for people living with visible and nonvisible disabilities.
iADH exists to improve desired oral health outcomes for people with disabilities and Oral-B exists to create the best oral care outcomes by providing the most rewarding and enjoyable oral care experiences for everyone, everyday – given our shared values, it felt like a very natural fit when Oral-B approached us to come together in partnership”
The brand will also be present at this year’s Biennial iADH Congress 2022 in Paris to learn from the global members, who will be sharing their knowledge and experience to improve oral health outcomes for people with disabilities in a KOL workshop hosted by Oral-B. The findings gathered from the workshop will help to inform Positive Practices and ensure that the training programme is underpinned by insight to deliver the best outcome for change.
-ENDS-
About Oral-B
Oral-B® exists to help people Brush Like a Pro. Oral-B® was founded in 1950 by a California periodontist, who invented an innovative toothbrush to help his patients achieve healthier teeth and gums at home. Oral-B® continues to stay true to his mission and is today the worldwide leader in the over $5 billion brushing market. Part of the Procter & Gamble Company, the brand manufactures electric toothbrushes and toothpaste for adults and children, oral irrigators, and interdental products.
About Procter & Gamble
P&G serves consumers around the world with one of the strongest portfolios of trusted, quality, leadership brands, including Always®, Ambi Pur®, Ariel®, Bounty®, Charmin®, Crest®, Dawn®, Downy®, Fairy®, Febreze®, Gillette®, Head & Shoulders®, Lenor®, Olay®, Oral-B®, Pampers®, Pantene®, SK-II®, Tide®, Vicks®, and Whisper®. The P&G community includes operations in approximately 70 countries worldwide. Please visit http://www.pg.com for the latest news and information about P&G and its brands.
About The iADH (International Association of Disability and Oral Health)
The iADH is a global organization with over 8000 members from all sectors of health and social care interested in disability and oral health who work to share their scientific knowledge, clinical skills and collective experience to reduce barriers to care and improve oral health outcomes for people with disability
1 The Oral Health & Disability European Study, March 2022, Oral-B
For more information, please visit: https://www.oralb.co.uk/en-gb
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220823005621/en/
Contact information
PR contact:
Melany Whitworth, Melany.whitworth@pgone.co.uk
Fraser McIntosh, fraser.mcintosh@pgone.co.uk
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 21:00:00 EET | Press release
Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham, MSc, MD, FRCPC, dermatologist, SKiN Centre for Dermatology, Peterborough, Ontario, Canada, principal investigator for the Latitude PsO studies and presenting author. “These efficacy and safety results show it’s possible for a once-daily pill to deliver rapid, lasting skin clearance, highlighting the potential of zasoc
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 21:00:00 EET | Press release
Incyte (Nasdaq:INCY) today announced 54-week data evaluating the safety and efficacy of povorcitinib (INCB54707), an oral small-molecule highly-selective JAK1 inhibitor, from the pivotal Phase 3 STOP-HS clinical trial program in adult patients (≥18 years) with moderate to severe hidradenitis suppurativa (HS). The late-breaking oral presentation of these data is taking place at the 2026 American Academy of Dermatology (AAD) Annual Meeting, being held March 27-31, 2026, in Denver (Session: S034 – Late-Breaking Research: Session 2. Saturday, March 28, 2026, 1:00-4:00 p.m. MT). “The 54-week results from the STOP-HS program deliver compelling, long-term evidence supporting the potential of povorcitinib for patients with moderate to severe HS,” said Pablo J. Cagnoni, M.D., President and Global Head of Research and Development, Incyte. “Across both studies, povorcitinib demonstrated substantial and durable improvements over time in key measures of treatment success and meaningful clinical ben
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 17:00:00 EET | Press release
Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-breaking session at the 2026 American Academy of Dermatology (AAD) Annual Meeting. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260328320362/en/ Atopic dermatitis is the most common inflammatory skin disorder in children, yet treatment options in the moderate-to-severe pediatric setting are limited.5 The disease can have a significant impact on quality of life for both the patients and their loved ones, with persistent itch and recurrent skin lesions often disrupting sleep, school and relationships.5-8 “Atopic dermatitis can affect many aspects of children’s lives including schoolwork, emotional development
Angelalign Technology (6699.HK) Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 21:56:00 EET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 19:46:00 EET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom